TY - JOUR PY - 2014// TI - Role of sertraline in posttraumatic brain injury depression and quality-of-life in TBI JO - Asian journal of neurosurgery A1 - Ansari, Ahmed A1 - Jain, Akhilesh A1 - Sharma, Achal A1 - Mittal, R. S. A1 - Gupta, I. D. SP - 182 EP - 188 VL - 9 IS - 4 N2 - INTRODUCTION: Traumatic brain injury (TBI) is a major cause of disability. Depression is one of the major squeal of TBI in both in-patient and out-patient populations. Depression is associated with numerous negative outcomes, thus affecting quality-of-life (QOL) adversely in these patients. Addressing depression in treatment regimen of TBI may improve QOL of these patients.

OBJECTIVE: The present study is designed to evaluate the role of sertraline in post TBI depression and its impact on QOL.

MATERIALS AND METHODS: Eighty male patients with post TBI depression were included in the study among the 250 male patients of mild to moderate TBI recruited for the evaluation. Half of the patients were given sertraline 50 mg PO, whereas other half served as control without sertraline treatment. Participants were assessed on Glasgow Coma scale, Patient Health Questionnaire-9 (PHQ-9) and World Health Organization QOL (WHOQOL) at regular interval till the end of 6 months.

RESULT: Depression was found in 35.6% of total patients recruited. Most of the patients (63.1%) were below 35 years of age. Depression was more common in mild TBI cases than those with moderate TBI (53.7% vs. 46.25%, P = 0.04). Left side brain injury (56.25%) with cerebral contusions was more commonly associated with depression (P = 0.04). Patients in sertraline group responded well to treatment with significant improvement in mod symptoms (PHQ-9 score 14.88 ± 3.603 vs. 5.33 ± 2.98, P = 0.04)). All the four domains of QOL improved significantly in sertraline group than the control group with sertraline treatment.

CONCLUSION: Management of TBI should also focus on treatment of associated mood symptoms, which is likely to be associated with poor QOL in these patients. Sertraline has been found to be effective in the treatment of depression with significant improvement in QOL in TBI patients.

Language: en

LA - en SN - 1793-5482 UR - http://dx.doi.org/10.4103/1793-5482.146597 ID - ref1 ER -